Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifico (Shanghai Sine Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- Shanghai Sine
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifico is a triple-combination probiotic formulation containing live Bifidobacterium longum (specifically strain 6-1), Lactobacillus acidophilus, and Enterococcus faecalis. Developed by Shanghai Sine Pharmaceutical, it is approved in China as an over-the-counter (OTC) and prescription drug for the treatment of gastrointestinal disorders associated with gut dysbiosis, including acute and chronic diarrhea, abdominal bloating, indigestion, and constipation. Bifico works by replenishing beneficial gut bacteria, producing lactic acid to create an acidic environment hostile to pathogens, and strengthening the intestinal mucosal barrier. In addition to its established gastrointestinal indications, Bifico is being investigated for its immunomodulatory and therapeutic potential in systemic sclerosis (SSc), Parkinson's disease, small intestinal bacterial overgrowth (SIBO), and postoperative depression in cancer patients.
- Brand names
- Bifico
- Other names
- B. longum/L. acidophilus/E. faecalis probiotic supplementBifidobacterium longum + Lactobacillus acidophilus + Enterococcus faecalisBifidobacterium longum/Lactobacillus acidophilus/Enterococcus faecalis supplementBifidobacterium triple viable capsulesBifidobacterium triple viable enteric-coated capsulesBifidobacterium triple viable probioticsLactobacillus acidophilus + Bifidobacterium longum 6-1 + Enterococcus faecalisLive Combined Bifidobacterium, Lactobacillus and Enterococcus Capsules
Beyond the preview
Go deeper on Bifico (Shanghai Sine Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifico (Shanghai Sine Pharmaceutical).